Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | PYGM | P11217 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119153 | 0.90 | NPY1R (0.45) | NPY1RSCN9A | |
| SCHEMBL7419284 | 0.88 | AADAT (0.40) | GAANFKB1NFKB2RELASCN9A | |
| SCHEMBL7423564 | 0.88 | KYAT1 (0.46) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL9974770 | 0.85 | LIPG (0.39) | NPY1REPHX2SCN9APYGLPYGM | |
| SCHEMBL9966166 | 0.84 | ESR2 (0.35) | ESR2ESR1PYGLPYGM | |
| SCHEMBL9974767 | 0.81 | DRD2 (0.37) | GAANFKB1NFKB2RELAKDM1A | |
| SCHEMBL24190214 | 0.79 | GAA (0.38) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL6762623 | 0.78 | BACE1 (0.41) | GAANFKB1NFKB2RELANPY1R | |
| SCHEMBL6832201 | 0.78 | BACE1 (0.41) | GAANFKB1NFKB2RELANPY1R | |
| SCHEMBL6762742 | 0.78 | BACE1 (0.41) | GAANFKB1NFKB2RELANPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GAA 125/4885ESR2 2695/4885NFKB1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.